Tags · Clinical
type 2 diabetes
The population with the largest evidence base for these compounds.
Related in this group: HbA1c · lipid panel · eGFR & renal function · liver enzymes · thyroid function · lipase & amylase · inflammatory markers · micronutrients · blood pressure · heart rate · chronic kidney disease · MASH / hepatic steatosis
65 topics · page 1 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Semaglutide formulation: what is in the licensed product besides the peptide
Semaglutide formulation: what is in the licensed product besides the peptide — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin semaglutide…
|
+29 | 35 | 4.4k | 1h |
|
About the Comorbidities category
Type 2 diabetes, hepatic steatosis, sleep apnoea, cardiovascular and renal disease. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 16k | 12h | |
|
Osteoarthritis and mechanical versus metabolic improvement
Osteoarthritis and mechanical versus metabolic improvement Writing it up because I had to work it out twice and would rather nobody else did. Asking about osteoarthritis and mechanical versus metabolic…
|
+2 | 6 | 30k | 12h |
|
Molecular mass of semaglutide and why the figure differs between sources
Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
|
+101 | 110 | 12k | 16h |
|
What a good consultation looks like from the other side
What a good consultation looks like from the other side — that is the question, and I have not found it answered plainly anywhere I have looked. Something about good consultation does not reconcile and I…
|
+57 | 62 | 4.9k | 22h |
|
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Trying to work out what would count…
|
+17 | 22 | 4.5k | 1d |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile
Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. Semaglutide and gastric emptying,…
|
+115 | 122 | 2.6k | 1d |
|
PCOS and metabolic overlap: what is and is not studied
On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. PCOS and metabolic overlap, from the point of view of someone who has read the…
|
3 | 6.6k | 1d | |
|
What to bring: records that a clinician can actually use
Asking directly, because I could not find a straight answer: What to bring: records that a clinician can actually use A question about how to describe something to a clinician rather than about the thing…
|
+15 | 19 | 6.4k | 1d |
|
[2026 update] Second opinions: how to seek one without burning the first
On the subject in the title: Second opinions: how to seek one without burning the first Working notes rather than a conclusion. Two things I would like separated before anyone answers on Second opinions,…
|
2 | 5.9k | 1d | |
|
Coming back to: Preparing for an appointment: one page, three questions
Preparing for an appointment: one page, three questions — setting out what I have, and where I think it stops being reliable. A question about how to describe something to a clinician rather than about the…
|
+51 | 56 | 1.4k | 2d |
|
Second pass at: When your prescriber and the evidence disagree
Second pass at: When your prescriber and the evidence disagree — setting out what I have, and where I think it stops being reliable. What changes if the standard account of prescriber is wrong? I ask because…
|
+51 | 55 | 9.2k | 2d |
|
Revisiting: PCOS and metabolic overlap: what is and is not studied
Revisiting: PCOS and metabolic overlap: what is and is not studied — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on PCOS and metabolic…
|
+55 | 59 | 26k | 2d |
|
When your prescriber and the evidence disagree
When your prescriber and the evidence disagree — that is the question, and I have not found it answered plainly anywhere I have looked. What changes if the standard account of prescriber is wrong? I ask…
|
+14 | 18 | 273 | 2d |
|
Semaglutide and alcohol: what is actually documented
Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I would like to know what people here actually do about semaglutide…
|
+14 | 18 | 10k | 2d |
|
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first…
|
+5 | 9 | 30k | 8d |
|
Heart failure with preserved ejection fraction: symptom endpoints
Heart failure with preserved ejection fraction: symptom endpoints — setting out what I have, and where I think it stops being reliable. Heart failure with preserved ejection keeps being re-asked here and I…
|
+19 | 23 | 311 | 12d |
|
Osteoarthritis and mechanical versus metabolic improvement — one year on
On the subject in the title: Osteoarthritis and mechanical versus metabolic improvement — one year on Working notes rather than a conclusion. Collecting what is known about Osteoarthritis and mechanical…
|
+52 | 56 | 8.1k | 15d |
|
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I would like to know what…
|
+23 | 27 | 9.9k | 1mo |
|
Gastro-oesophageal reflux: improving or worsening?
The question in the title: Gastro-oesophageal reflux: improving or worsening? I will give what I have already checked below so nobody repeats it. Collecting what is known about gastro-oesophageal reflux in…
|
+54 | 58 | 8.2k | 1mo |
|
[2026 update] What a good consultation looks like from the other side
The question in the title: What a good consultation looks like from the other side I will give what I have already checked below so nobody repeats it. Good consultation: what I expected, what I found, and the…
|
+32 | 36 | 13k | 1mo |
|
Getting a referral rather than a refusal
Getting a referral rather than a refusal — setting out what I have, and where I think it stops being reliable. What changes if the standard account of getting a referral is wrong? I ask because I have been…
|
+8 | 12 | 32k | 2mo |
|
Is there a ceiling dose beyond which semaglutide stops adding benefit?
Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because…
|
2 | 14k | 2mo | |
|
What the published dose-response for semaglutide actually looks like above 2.4 mg
What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people here…
|
2 | 10k | 3mo | |
|
Type 2 diabetes and the largest part of the evidence base
Posting this under the heading it deserves: Type 2 diabetes and the largest part of the evidence base Everything below is what sits behind that. Trying to work out what would count as evidence on type 2…
|
+81 | 89 | 2.9k | 3mo |
|
Why semaglutide solutions can look faintly opalescent and when that matters
The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. A follow-up question about…
|
+73 | 79 | 2k | 4mo |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
|
+128 | 145 | 3k | 4mo |
|
The most common factual error about semaglutide on the internet — what changed since
The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a…
|
+42 | 46 | 1.7k | 5mo |
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Putting the numbers in the first post, because a question about a…
|
2 | 63k | 5mo | |
|
Cardiovascular risk: reading the outcome trials as a set
Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Reading back through what has been written here about cardiovascular…
|
4 | 12k | 5mo |